Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Medicine Excipients
Veterinary raw materials
WeChat: 15091775531
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Suplatast Tosilate Powder Raw Material
Product Overview:
China Suplatast Tosilate Raw Material Manufacturer Supply Suplatast Tosilate API CAS 94055-76-2 Factory Price of Suplatast Tosilate Powder from Henrikang.
Suplatast Tosilate Powder Raw Material Attributes
Product Name: Suplatast Tosilate Powder Raw Material
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Specification: 99% min Suplatast Tosilate
Test Method: HPLC
CAS: 94055-76-2
MF: C23H33NO7S2
Sample: Suplatast Tosilate Powder
Keywords: Suplatast Tosilate Supplier, Suplatast Tosilate API, China Suplatast Tosilate Manufacturer
Suplatast Tosilate Powder Raw Material Details
Use and synthesis method of Suplatast Tosilate :
Suplatast Tosilate , chemical name (2-(4-(3-ethoxy-2-hydroxy-propyloxy) phenyl carbamyl) ethyl) dimethyl sulfonate, is a selective Th2 cytokine inhibitor developed by Taiho Pharmaceutical Company in Japan, and launched in Japan in 1995. Domestic and foreign studies have shown that it can selectively inhibit the extravascular migration of helper T cells, lymphocytes, monocytes and eosinophils, reduce the inflammation of airway eosinophils, reduce the production of inflammatory mediators IL-4, IL-5, IL-13 and IFN-γ, and reduce the levels of serum histamine, eosinophin cationic protein and IgE. Reduce airway hyperreactivity, which may play a role through the active metabolite 4-(3-ethoxy-2-hydroxy-propyl) -allylaniline (M-1) in vivo, block the differentiation, maturation and function of monocytes into dendritic cells (DC), and increase the ratio of DC1/DC2, promoting the enhancement of Th1 reaction; Meanwhile, it can inhibit mast cell degranulation mediated by specific IgE antibody and release of inflammatory mediators, reduce symptom score, improve lung function, reduce the dosage of β2 receptor agonist, and have a "hormone saving" effect. The drug has been marketed in foreign countries and has become a commonly used drug in clinical practice, mainly used in the treatment of bronchial asthma, allergic rhinitis allergic dermatitis and eosinophilia syndrome, and has also been reported to treat vitiligo and hepatitis C.
Pharmacological effects of Suplatast Tosilate :
Suplatast Tosilate is a novel selective cytokine inhibitor, which can selectively inhibit helper T cells and reduce the production of inflammatory mediators IL-4 and IL-5, thereby inhibiting the extravascular migration of lymphocytes, monocytes and eosinophils and reducing the airway infiltration inflammation caused by airway eosinophils. Inhibition of specific antibody IgE mediated mast cell degranulation and release of inflammatory mediators, thereby reducing airway inflammatory response.
Suplatast Tosilate , chemical name (2-(4-(3-ethoxy-2-hydroxy-propyloxy) phenyl carbamyl) ethyl) dimethyl sulfonate, is a selective Th2 cytokine inhibitor developed by Taiho Pharmaceutical Company in Japan, and launched in Japan in 1995. Domestic and foreign studies have shown that it can selectively inhibit the extravascular migration of helper T cells, lymphocytes, monocytes and eosinophils, reduce the inflammation of airway eosinophils, reduce the production of inflammatory mediators IL-4, IL-5, IL-13 and IFN-γ, and reduce the levels of serum histamine, eosinophin cationic protein and IgE. Reduce airway hyperreactivity, which may play a role through the active metabolite 4-(3-ethoxy-2-hydroxy-propyl) -allylaniline (M-1) in vivo, block the differentiation, maturation and function of monocytes into dendritic cells (DC), and increase the ratio of DC1/DC2, promoting the enhancement of Th1 reaction; Meanwhile, it can inhibit mast cell degranulation mediated by specific IgE antibody and release of inflammatory mediators, reduce symptom score, improve lung function, reduce the dosage of β2 receptor agonist, and have a "hormone saving" effect. The drug has been marketed in foreign countries and has become a commonly used drug in clinical practice, mainly used in the treatment of bronchial asthma, allergic rhinitis allergic dermatitis and eosinophilia syndrome, and has also been reported to treat vitiligo and hepatitis C.
Pharmacological effects of Suplatast Tosilate :
Suplatast Tosilate is a novel selective cytokine inhibitor, which can selectively inhibit helper T cells and reduce the production of inflammatory mediators IL-4 and IL-5, thereby inhibiting the extravascular migration of lymphocytes, monocytes and eosinophils and reducing the airway infiltration inflammation caused by airway eosinophils. Inhibition of specific antibody IgE mediated mast cell degranulation and release of inflammatory mediators, thereby reducing airway inflammatory response.
